Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma

Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma

The protein kinase V-Raf murine sarcoma viral oncogene homolog B (BRAF) is an oncogenic driver and therapeutic target in melanoma. Inhibitors of BRAF (BRAFi) have shown high response rates and extended survival in melanoma patients bearing tumors that express BRAF Val600 mutations, but a vast majori...

Full description

Bibliographic Details
Main Authors: Shen, Che-Hung, Kim, Sun Hye, Trousil, Sebastian, Frederick, Dennie T., Piris, Adriano, Yuan, Ping, Cai, Li, Gu, Lei, Li, Man, Lee, Jung Hyun, Mitra, Devarati, Fisher, David E., Sullivan, Ryan J., Flaherty, Keith T., Zheng, Bin
Format: Online
Language:English
Published: 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014622/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014622/

Similar Items